awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47100805-664D53BF-4144-403A-84B4-7F581D94DD58
Q47100805-664D53BF-4144-403A-84B4-7F581D94DD58
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47100805-664D53BF-4144-403A-84B4-7F581D94DD58
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.
P2860
Q47100805-664D53BF-4144-403A-84B4-7F581D94DD58
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47100805-664D53BF-4144-403A-84B4-7F581D94DD58
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0266c359179697a3a8004d915bcccc619c873475
P2860
Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.